Editorial: Terlipressin Induced Bradycardia

Affiliations

Editorial

Nancy Reau et al. Aliment Pharmacol Ther. 2025.

. 2025 Sep 26.

doi: 10.1111/apt.70336. Online ahead of print.

¹ Division of Digestive Disease and Nutrition, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.

No abstract available

References

1. S. W. Biggins, P. Angeli, G. Garcia‐Tsao, et al., “Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases,” Hepatology 74, no. 2 (2021): 1014–1048, https://doi.org/10.1002/hep.31884.
1. Mallinckrodt Pharmaceuticals, “Terlivaz (terlipressin) for injection [Prescribing Information],” U.S. Food and Drug Administration website, 2022, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf.
1. J. Skvarce, A. Bui, P. Oro, et al., “Multisystem Hemodynamic Effects of Terlipressin in Cirrhosis: A Scoping Review,” Journal of Critical Care 87 (2025): 155038, https://doi.org/10.1016/j.jcrc.2025.155038.
1. J. S. Bajaj, P. Kwo, S. C. Pappas, et al., “Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies,” Alimentary Pharmacology & Therapeutics (2025): 1–10, https://doi.org/10.1111/apt.70297.
1. M. K. Nadim, J. A. Kellum, L. Forni, et al., “Acute Kidney Injury in Patients With Cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) Joint Multidisciplinary Consensus Meeting,” Journal of Hepatology 81, no. 1 (2024): 163–183, https://doi.org/10.1016/j.jhep.2024.03.031.